Live Breaking News & Updates on University Hospital In Leipzig
Stay updated with breaking news from University hospital in leipzig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bad news for allergy sufferers: warmer weather in Germany means pollen season has started early, researchers at Leipzig University’s Hospital have announced. ....
In a dramatic step toward eradicating medical error, software developers XANTAS worked with SAP to create a Critical Decision Support System to accurately read lab values and help clinicians make informed decisions. ....
Thousands Protest in Germany against Compulsory Vaccination - Novinite.com novinite.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novinite.com Daily Mail and Mail on Sunday newspapers.
(2) Wearable cardiac monitoring solution enables early detection and treatment of arrhythmia based on risk factors, according to results of the SCREEN-AF study published in JAMA Cardiology iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new SCREEN-AF study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner ....
LEXINGTON, Mass., Feb. 2, 2021 /PRNewswire/ Curis, Inc., (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the initiation of a Phase 2 investigator-sponsored trial (IST) evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, for the treatment of anemia in patients with very low, low, or intermediate-risk myelodysplastic syndromes (MDS). The study is being led by Uwe Platzbecker, M.D., Ph.D., Professor and Director of the Medical Clinic and Polyclinic for Hematology, Cell Therapy, and Hemostaseology at the University Hospital in Leipzig. Dr. Platzbecker is co-founder and chairman of both the European Myelodysplastic Syndromes Cooperative Group (EMSCO) and the German MDS Study Group (D-MDS). Furthermore, he acts as co-chairman of the European Hematology Association s Scientific Working Group on MDS. ....